Biosimilar Drug Market Analysis 2026

Additional Insights in Biosimilar Drug Market

Regulation And Guidelines for the Biosimilar Market

• North America
• Europe
• Asia Pacific
• South America
• Middle East
• Africa

The U.S. Food and Drug Administration (FDA) regulates biologics and biosimilars under a robust and structured framework designed to ensure safety, efficacy, and product quality. Biologics are complex, large-molecule therapies derived from living organisms and include categories such as therapeutic proteins, monoclonal antibodies, vaccines, blood components, and gene/cell therapies. Biosimilars, on the other hand, are highly similar versions of FDA-approved biologics, with no clinically meaningful differences. Interchangeable biosimilars go a step further by meeting additional standards that allow them to be substituted at the pharmacy level without prescriber involvement. The Biologics Price Competition and Innovation Act (BPCIA), enacted in 2010, provides the legal foundation for biosimilar approvals, creating an abbreviated regulatory pathway similar to that used for generics.

The regulatory process for both biologics and biosimilars includes several phases: preclinical development, submission of an Investigational New Drug (IND) application, and clinical trials across Phases 1–3. For final approval, manufacturers must submit a Biologics License Application (BLA) or biosimilar application, which includes detailed data such as manufacturing processes (CMC), clinical trial results, immunogenicity assessments, comparative analytical studies (for biosimilars), and safety data. The FDA’s Center for Drug Evaluation and Research (CDER) oversees these reviews. Post-marketing surveillance, risk management plans, and patent information are also essential parts of the regulatory lifecycle, ensuring continued patient safety and product quality throughout a biologic or biosimilar’s market presence.

(Source:https://www.artixio.com/post/biologics-and-biosimilars-regulations-registration-usa-fda)

Clinical Pipeline Analysis

 

Sr No.	Company	Drug	Phase	Indication
1	Samsung Bioepis	SB2: Remicade biosimilar	Phase III	Autoimmune Disease Treatments
		SB4: Enbrel biosimilar
		SB5: Humira biosimilar
2	Samsung Bioepis	SB17 (Stellara biosimilar, ingredient name: Ustekinumab)	Phase III	Plaque Psoriasis

Samsung Bioepis has commenced a Phase 3 clinical trial for SB17, its 10th biosimilar candidate and a biosimilar to Stelara (Ustekinumab), targeting 464 patients with moderate to severe plaque psoriasis across eight countries including South Korea, Poland, and the Czech Republic. This follows a Phase 1 trial on 201 healthy adults in France earlier this year, enabling accelerated development. Stelara, originally developed by Janssen, treats immune-related conditions such as psoriasis, Crohn’s disease, and ulcerative colitis, with global sales reaching approximately USD 7.77 billion in 2020. The advancement of SB17 reflects Samsung Bioepis’s commitment to broadening access to autoimmune therapies and aligns with its strategic growth in biosimilars during its 10th anniversary year. The company currently markets five biosimilars globally—including treatments for autoimmune and cancer conditions—and is expanding into other therapeutic areas with four additional biosimilars, including SB17, now in Phase 3 development for autoimmune, ophthalmic, blood, and skeletal diseases.

(Source:https://www.biosimilardevelopment.com/doc/samsung-bioepis-begins-phase-clinical-trial-for-stellara-biosimilar-sb-0001)

Conferences and Events in Biosimilar Drugs Market

The global biosimilars sector continues to evolve rapidly, with major conferences offering valuable platforms for industry leaders, regulators, healthcare professionals, and policymakers to collaborate, share insights, and shape the future of biotherapeutics.

Biosimilar Medicines Conference 2025
Theme: Fuelled by the Past, Gearing Up for the Future
Date & Venue: April 3–4, 2025 | Hilton Amsterdam Airport Schiphol, Netherlands

Hosted annually, this flagship event brings together stakeholders from across the biosimilar ecosystem to discuss strategic, regulatory, and access-driven topics. Key themes include optimizing biotherapy access, balancing market dynamics with long-term health goals, the evolving role of patients and clinicians in adoption, and the future of advanced therapy biosimilars in Europe. The conference emphasizes the need to streamline development, enhance competitiveness, and align biosimilar policy with broader healthcare sustainability and innovation goals.

Emerging Biosimilars in Therapeutics
Date: March 14–15, 2024 | London, UK

This forum focuses on the expanding pipeline of biosimilars in development, especially in high-demand areas like diabetology, oncology, and autoimmune diseases. Discussions include market readiness of biosimilars for drugs like Adalimumab, Etanercept, Trastuzumab, and Pegfilgrastim, as well as the increasing market dominance of certain biosimilars (e.g., Remicade, Eprex, Neupogen) in Europe. Market trends, R&D strategies, and regulatory pathways for low molecular weight heparins, epoetins, insulin biosimilars, and other therapeutic classes are also highlighted.

These conferences provide critical opportunities to explore how biosimilars can improve patient access, reduce healthcare costs, and stimulate industrial innovation.

(Source:http://medicinesforeurope.com/events/bios25)

Pricing Analysis of the Biosimilar Drugs Market

Biosimilar drugs typically offer price discounts of 15–35% compared to their reference biologics, which is significantly less than the approximately 75% reductions seen with generic drugs due to the complexity and production costs involved. In the U.S., biosimilars for oncology and pegfilgrastim have achieved strong market penetration, capturing about 81% market share within five years and averaging 52% in the first year. In contrast, biosimilars for immunology, filgrastim, epoetin alfa, and insulin glargine have reached only around 26% market share over the same period. Wholesale Acquisition Cost (WAC) discounts vary by drug, with trastuzumab, bevacizumab, and rituximab biosimilars offering reductions of approximately 49% to 66%, while adalimumab biosimilars like Hadlima and Yusimry reach up to 85–86% discounts compared to Humira. Globally, pricing dynamics are influenced by local regulations; for example, in Finland, reimbursement policies caused reference biologic prices to drop after biosimilar launches, but biosimilar prices remained relatively stable, limiting competitive pricing. In markets like India, biologic prices such as somatropin show over 180% variability based on brand and supplier. Regulatory frameworks, tendering systems, and rebate mechanisms in countries like the U.S. often complicate biosimilar uptake despite price reductions, while many emerging markets impose mandatory discounts of 30–40% to boost access. Overall, while biosimilar discounts are meaningful, uptake and pricing are shaped by complex market and policy factors, with greater adoption in oncology and emerging markets. For a detailed analysis of market share, pricing trends, and uptake in Q1 2025, see the comprehensive report linked here.

(Source:https://pmc.ncbi.nlm.nih.gov/articles/PMC9938002/m)

Value chain analysis of the Biosimilar Market

A value chain analysis of biosimilar drugs outlines the sequential processes that create value and drive cost-efficiency across the product lifecycle. It begins with Research & Development (R&D), where value is generated through high-quality analytical characterization, reference product selection, and the strategic use of AI to accelerate clinical trial design—despite the high costs and regulatory uncertainties involved. In the manufacturing phase, activities such as cell line development, bioprocessing, and formulation are critical, with value driven by process scalability, quality control, and cost-effective production, though challenges include complex biologic variability and capital-intensive infrastructure. The regulatory approval stage adds value through strong comparability data and harmonized submissions, yet navigating different global regulatory pathways and ensuring post-approval compliance remains a hurdle. Next, the distribution and supply chain phase focuses on packaging and cold-chain logistics, where efficiency, global reach, and strategic partnerships are essential, though disruptions from tariffs and the temperature-sensitive nature of biologics can complicate delivery. Market access and pricing activities such as reimbursement negotiations, payer engagement, and formulary placement determine commercial viability, with value tied to competitive pricing and early access—but barriers like price erosion and rebate-driven resistance persist. Sales, marketing, and adoption involve educating stakeholders and building trust using real-world evidence, but are challenged by prescriber loyalty to reference biologics and limited incentives to switch. Finally, post-marketing surveillance ensures long-term safety and efficacy through pharmacovigilance and AI-driven real-world data analytics, though data fragmentation and regulatory scrutiny remain ongoing concerns. Together, these stages define where and how value is created, sustained, or lost in the biosimilar drug ecosystem.

(Source:https://www.mdpi.com/2076-3417/14/17/7529)

Government Investment and Program for the Global Biosimilar Drugs

Government initiatives and investments in biosimilars across the globe are accelerating development, enhancing regulatory efficiency, and improving access to affordable biologics. In the United States, the Biosimilar User Fee Act (BsUFA) funds timely FDA reviews, while the FDA’s Biosimilars Action Plan (BAP) promotes clarity, competition, and education. The European Union, through the €2 billion Innovative Medicines Initiative (IMI), has supported biosimilar R&D and regulatory science. India has launched robust programs via DBT and BIRAC—such as BIPP, NBM, and the 2024 BioE3 Policy—to co-fund biosimilar development, scale domestic manufacturing, and introduce AI-enabled biofoundries. Canada’s provincial governments have implemented transition programs that generate hundreds of millions in savings by shifting to biosimilars, reinvesting in healthcare. Globally, public–private partnerships and World Health Organization (WHO) efforts aim to improve regulatory harmonization, technology transfer, and local manufacturing in low- and middle-income countries. These strategic actions underscore the growing governmental commitment to making biosimilars more accessible, cost-effective, and globally integrated.

(Source:https://www.who.int/news/item/13-02-2025-biosimilars--expanding-access-to-essential-biologic-therapies?)

Reimbursement Policies in the Global Biosimilar Drugs Market

Biosimilar reimbursement policies play a pivotal role in shaping market uptake and pricing strategies across global healthcare systems. In the United States, Medicare Part B reimburses biosimilars at the originator's Average Sales Price (ASP) plus 8%, which can inadvertently discourage biosimilar use due to lower reimbursement tied to their typically lower ASP. Additionally, Pharmacy Benefit Managers (PBMs) often favor originator biologics through rebate-driven formularies, further limiting biosimilar access despite their cost advantages. In Europe, many countries utilize tender-based or internal reference pricing models, with nations like Bulgaria and Croatia reimbursing biosimilars at parity with originators, encouraging physicians to prescribe them for new patients. Canada has adopted mandatory non-medical switching (NMS) policies in provinces such as British Columbia, Alberta, and Ontario, requiring patients to switch from originators to biosimilars, resulting in significant cost savings. Japan incentivizes biosimilar prescribing through modest physician bonuses, such as ¥1,500 for trastuzumab prescriptions, contributing to higher biosimilar uptake. On a global scale, the World Health Organization supports harmonized reimbursement frameworks, advocating for the inclusion of biosimilars in essential medicine lists and procurement systems to expand access in low- and middle-income countries.

(Source:https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-payer-and-pbm-policies)

Unmet Needs of Global Biosimilar Drugs Market

Unmet needs in the biosimilar drug landscape highlight several ongoing challenges that restrict their full potential to improve access and affordability of biologic therapies. A major issue is the lack of physician and patient awareness, with many still skeptical about biosimilars' efficacy, safety, and immunogenicity—especially concerning switching from reference products—which limits their uptake. Regulatory harmonization remains fragmented globally, as varying guidelines, data requirements, and interchangeability rules across regions such as the U.S., EU, and India complicate development, raise costs, and delay market entry. Clear, evidence-based policies on interchangeability and automatic substitution are often absent, making biosimilar adoption dependent on individual clinicians and limiting pharmacy-level substitution. Reimbursement and incentive structures are inconsistent, with systems like Medicare in the U.S. sometimes disincentivizing biosimilar use, while rebate deals between originators and payers or pharmacy benefit managers can further restrict biosimilar formulary inclusion. Market access is also challenged by tendering systems that favor winner-takes-all approaches, which can stifle competition and long-term market sustainability. Additionally, manufacturing and supply chain complexities demand advanced infrastructure and quality controls that are often lacking, particularly in low- and middle-income countries, making consistent supply and cost-effective production difficult. Post-marketing surveillance and pharmacovigilance systems are underdeveloped in many regions, hampering the collection of long-term safety and effectiveness data, which undermines trust and regulatory confidence. Finally, patient access in low-income regions remains limited due to weak regulatory frameworks, poor distribution networks, and insufficient government funding or insurance coverage, preventing many from benefiting from these cost-effective therapies.

(Source:https://www.mdpi.com/1648-9144/58/11/1533?)

Competitive Landscape of Biosimilar Drug Market

Established Market Players

• Amgen Inc.
• Pfizer Inc.
• Samsung Bioepis
• Sandoz Group AG
• Biocon
• Others

The established players in the biosimilar drugs market—such as Amgen, Pfizer, Sandoz, Samsung Bioepis, and Biocon leverage strong R&D capabilities, global regulatory experience, and extensive distribution networks to maintain leadership. These companies have broad biosimilar portfolios targeting high-value biologics like adalimumab, trastuzumab, and bevacizumab. Their early market entry and strategic partnerships (e.g., Biocon-Viatris, Samsung Bioepis-Biogen) have helped secure regulatory approvals across the U.S., EU, and emerging markets. However, they now face increasing pressure from pricing erosion, the need for innovation beyond biosimilars, and competition from more agile, cost-efficient challengers.

Emerging Market Players

• Celltrion Healthcare Canada Limited 
• Alvotech
• Fresenius Kabi USA, LLC. 
• Accord Healthcare
• Others

In contrast, emerging players like Celltrion, Alvo tech, Accord Healthcare, and Fresenius Kabi are gaining traction by offering competitively priced products and focusing on niche areas or interchangeable biosimilars. These companies often operate with leaner models, allowing for faster turnaround and aggressive pricing, particularly in Europe and North America. While they lack the brand recognition and global scale of incumbents, many have rapidly expanded via strategic regional launches or partnerships. Their key challenges include regulatory hurdles, limited commercial infrastructure, and competition from both premium and low-cost biosimilar providers, but their growth signals a shift toward market democratization.

Recent Developments in Biosimilar Drug Market

February 2025, 

The FDA approved Celltrion’s Stoblo and Osenvelt (denosumab-bmwo), biosimilars to Amgen’s Prolia and Xgeva. This approval is a key milestone for complex biosimilars, expected to lower treatment costs, expand patient access, and drive broader adoption of biosimilars in both osteoporosis and oncology care.

(Source:https://www.gabionline.net/biosimilars/news/fda-approves-denosumab-biosimilars-stoboclo-and-osenvelt)

May 2025

The EMA’s CHMP recommended approval of three denosumab biosimilars—Bomyntra and Conexxence by Fresenius Kabi, and Rolcya by Sandoz. This is expected to boost biosimilar adoption in Europe by increasing competition, lowering costs, and improving patient access to osteoporosis and oncology treatments.

(Source:https://www.gabionline.net/biosimilars/news/fda-approves-denosumab-biosimilars-stoboclo-and-osenvelt)

Market Strategies by the Players

Product Launches:

The biosimilar drug market has seen accelerated product launches as manufacturers aim to capitalize on expiring biologic patents and growing demand for affordable biologics. In recent years, companies like Samsung Bioepis, Sandoz, and Biocon have expanded their biosimilar portfolios, targeting key therapeutic areas such as oncology, autoimmune diseases, and diabetes. The launch of biosimilars for blockbuster biologics like trastuzumab, adalimumab, and rituximab has significantly increased treatment options for patients worldwide. Players are increasingly focusing on complex molecules that require advanced development capabilities, such as monoclonal antibodies and fusion proteins. Innovations in manufacturing and robust clinical data packages have facilitated regulatory approvals, enabling faster market entry and wider acceptance among healthcare providers. For instance, Biocon’s launch of biosimilar insulins and oncology drugs has helped improve accessibility in emerging markets like India and Canada. In February 2025, Sandoz and Biocon Biologics launched their biosimilar versions of Johnson & Johnson’s Stelara (ustekinumab). Samsung Bioepis developed Pyzchiva (ustekinumab-ttwe), commercialized by Sandoz, which is expected to gain interchangeability status in early 2025. Both Pyzchiva and Biocon’s Yesintek (ustekinumab-kfce) treat conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. They are available in various formulations, including pre-filled syringes and single-dose vials for subcutaneous and intravenous use.
(Source:https://www.managedhealthcareexecutive.com/view/two-more-stelara-biosimilars-launch)

Expansion Initiatives:

To meet rising global demand, biosimilar manufacturers are aggressively expanding manufacturing capacities and geographic footprints. Leading firms like Celltrion and Pfizer Biosimilars are investing in state-of-the-art biologics production facilities, particularly in Asia and Europe, to increase supply chain resilience and meet regulatory requirements. Expansion efforts also involve securing approvals across multiple regulatory agencies including FDA, EMA, and emerging markets, supporting a global commercialization strategy. Collaborations with local partners help improve distribution channels and patient access in underserved regions. These initiatives not only drive business growth but also play a critical role in making biologic therapies more affordable and available, especially in low- and middle-income countries where cost barriers have traditionally limited access. In July 2025, biosimilar developers Sandoz, STADA, and Samsung Bioepis each reported strong financial results fueled by robust biosimilar performance. The collective momentum underscores the accelerating commercial success and profitability of biosimilars globally, particularly in immunology and oncology, positioning these companies for continuous growth through expanded portfolios and new product launches.

(Source:https://www.centerforbiosimilars.com/view/sandoz-stada-and-samsung-bioepis-report-strong-earnings-from-biosimilars)

Partnerships:

Strategic alliances are vital in the biosimilar industry to leverage complementary expertise in biologics development and manufacturing. In 2023, numerous partnerships were announced between biosimilar developers and contract manufacturing organizations (CMOs), biotechnology firms, and research institutions. For example, Sandoz has collaborated with leading biotech firms to co-develop next-generation biosimilars with improved delivery systems and enhanced clinical profiles. These partnerships reduce development timelines and mitigate financial risks associated with complex biologic products. They also often include technology transfer agreements and shared regulatory strategies, enabling faster access to multiple markets. Such cooperative models are crucial to address the scientific and regulatory challenges unique to biosimilars, ensuring timely availability of high-quality, cost-effective biologics globally.

Acquisitions:

Mergers and acquisitions have become strategic tools for biosimilar companies aiming to broaden their product pipelines, enhance manufacturing capabilities, and expand market reach. Leading companies such as Viatris and Amgen have actively acquired smaller biosimilar developers and specialized manufacturing firms to enhance their biosimilar portfolios. In 2023, acquisitions targeted firms with innovative biosimilar candidates or advanced cell culture and bioprocessing capabilities. These strategic moves accelerate market entry into new therapeutic areas and regions, boost economies of scale, and add valuable regulatory and clinical expertise. Overall, mergers and acquisitions play a crucial role in driving growth, fostering innovation, and expanding patient access to cost-effective biologic therapies.

(Source:https://www.pharmavoice.com/news/2023-biosimilar-industry-acquisitions/)